These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18001625)

  • 41. PRO: Should aspirin be used in all women older than 65 years to prevent stroke?
    Hsia J
    Prev Cardiol; 2007; 10 Suppl 4():6-11. PubMed ID: 17917525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.
    Rothwell PM; Cook NR; Gaziano JM; Price JF; Belch JFF; Roncaglioni MC; Morimoto T; Mehta Z
    Lancet; 2018 Aug; 392(10145):387-399. PubMed ID: 30017552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
    BMJ; 1994 Jan; 308(6921):81-106. PubMed ID: 8298418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aspirin for first-line heart attack prevention. These is still no consensus; the benefits must be weighed against the risks.
    Duke Med Health News; 2014 Nov; 20(11):5-6. PubMed ID: 25481928
    [No Abstract]   [Full Text] [Related]  

  • 45. Antiplatelet therapy in the treatment of cerebrovascular disease.
    Couch JR
    Clin Cardiol; 1993 Oct; 16(10):703-10. PubMed ID: 8222382
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patient preference-based treatment thresholds and recommendations: a comparison of decision-analytic modeling with the probability-tradeoff technique.
    Man-Son-Hing M; Laupacis A; O'Connor AM; Coyle D; Berquist R; McAlister F
    Med Decis Making; 2000; 20(4):394-403. PubMed ID: 11059472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
    Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
    Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of antiplatelet drugs in the prevention of cardiovascular events.
    Tendera M; Wojakowski W
    Thromb Res; 2003 Jun; 110(5-6):355-9. PubMed ID: 14592562
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiplatelet agents and randomized trials.
    Diener HC
    Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.
    Pignone M; Williams CD
    Nat Rev Endocrinol; 2010 Nov; 6(11):619-28. PubMed ID: 20856266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study.
    Wu IC; Hsieh HM; Wu MT
    BMJ Open; 2015 Jan; 5(1):e006694. PubMed ID: 25575876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
    Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
    BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
    Bhatt DL; Fox KA; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Flather MD; Haffner SM; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Brennan DM; Fabry-Ribaudo L; Booth J; Topol EJ;
    N Engl J Med; 2006 Apr; 354(16):1706-17. PubMed ID: 16531616
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
    Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U
    Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Does aspirin have a place in primary cardiovascular prevention by the polypill ? Simulation study on a realistic virtual population].
    Fall M; Grenet G; Le HH; Kassaï B; Lega JC; Boussageon R; Mainbourg S; Marchant I; Gafsi J; Dieye AM; Gueyffier F
    Therapie; 2023; 78(6):667-678. PubMed ID: 36841655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aspirin for the prevention of cardiovascular disease.
    Lin KW
    Am Fam Physician; 2011 Jun; 83(12):1469-70. PubMed ID: 21671548
    [No Abstract]   [Full Text] [Related]  

  • 57. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.
    Anand SS; Yusuf S
    JAMA; 1999 Dec; 282(21):2058-67. PubMed ID: 10591389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    ; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
    N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aspirin: promise and resistance in the new millennium.
    Patrono C; Rocca B
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):s25-32. PubMed ID: 18174450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Anticoagulation and antiaggregation in cardiac patients].
    Meyer BJ
    Ther Umsch; 2003 Jan; 60(1):27-32. PubMed ID: 12638475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.